Cryoport, Inc. (CYRX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$16.77

From 52W high−0.64%

Volume775193.00

Market cap$862.05M

P/E (TTM)—

P/S (TTM)4.6x

Div yield—

Key dataSep 18, 2026

Open

$16.77

From 52W high

−0.64%

Volume

775193.00

Market cap

$862.05M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−237.7x

P/E (TTM)

—

RSI (14)

60.9

MomentumView details →

1D Return

+1.43%

YTD Return

+74.19%

SummaryUpdated Jun 1, 2026

Cryoport, Inc. (NASDAQ:CYRX) is a Tennessee-based life sciences services company founded in 1999 that specializes in temperature-controlled logistics solutions for the biotechnology and pharmaceutical industries. The company went public in 2005 and has evolved from a niche cryogenic shipping provider into a comprehensive logistics platform serving the rapidly growing cell and gene therapy market. Today, Cryoport operates globally across the Americas, Europe, the Middle East, Africa, and Asia Pacific, supporting over 675 clinical trials and 14 commercial therapies through its integrated suite of logistics services and cryogenic systems.

Ask drillr about Cryoport, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−237.7x

EV/Sales

4.0x

P/S (TTM)

4.6x

P/B (TTM)

1.8x

ProfitabilityView details →

Gross Margin

47.08%

Net Margin

−19.45%

EBITDA Margin

−1.68%

ROE (TTM)

−7.39%

ROA (TTM)

−4.80%

Asset Turnover

0.25x

GrowthView details →

Revenue YoY

−8.01%

EPS YoY

—

FCF YoY

+37.01%

Revenue CAGR 3Y

−7.50%

EPS CAGR 3Y

+163.35%

EBITDA YoY

+27.74%

MomentumView details →

1D Return

+1.43%

YTD Return

+74.19%

1Y Return

+67.73%

RSI (14)

60.9

vs 50D SMA

+5.94%

vs 200D SMA

+37.67%

Capital & dividendView details →

Debt/Equity

0.47x

Current Ratio

2.08x

Quick Ratio

1.98x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.20

EPS Surprise

−3.45%

Beats (12Q)

3/12

Next Q EPS Est

−$0.18

Avg Surprise (4Q)

−6.16%

Rev Surprise

1.65%

Financials snapshotView financials →

Revenue (TTM)

186.45M

Net Income (TTM)

−36.27M

Op. CF (TTM)

7.97M

Next earningsNov 3, 2026 →

Latest newsMore news →

Cryoport's IntegriCell cryopreservation services were selected by Verismo Therapeutics to support its clinical KIR-CAR T cell therapy programs.87d ago

Similar companies

CN Logistics International Holdings Limited02130.HK Guangdong Yueyun Transportation Company Limited03399.HK FAR International Holdings Group Company Limited02516.HK Infinity Logistics and Transport Ventures Limited01442.HK Yues International Holdings Group Limited01529.HK Forward Air CorporationFWRD Find similar companies →

Latest newsMore news →

Cryoport reported its second quarter 2026 financial results, with revenue growing 8% year-over-year to $49.0 million and Life Sciences Services revenue up 15%, BioStorage/BioServices revenue up 25%, supporting 779 global clinical trials and 22 commercially approved cell and gene therapies as of June 30, 2026.45d ago Cryoport's IntegriCell cryopreservation services were selected by Verismo Therapeutics to support its clinical KIR-CAR T cell therapy programs.87d ago